| Correction of laminin-5 deficiency in human epidermal stem cells by transcriptionally targeted lentiviral vectors F Di Nunzio, G Maruggi, S Ferrari, E Di Iorio, V Poletti, M Garcia, ... Molecular Therapy 16 (12), 1977-1985, 2008 | 89 | 2008 |
| Interactions between retroviruses and the host cell genome V Poletti, F Mavilio Molecular Therapy-Methods & Clinical Development 8, 31-41, 2018 | 83 | 2018 |
| Efficient non-viral gene delivery into human hematopoietic stem cells by minicircle sleeping beauty transposon vectors M Holstein, C Mesa-Nuñez, C Miskey, E Almarza, V Poletti, M Schmeer, ... Molecular therapy 26 (4), 1137-1153, 2018 | 70 | 2018 |
| Designing lentiviral vectors for gene therapy of genetic diseases V Poletti, F Mavilio Viruses 13 (8), 1526, 2021 | 49 | 2021 |
| Preclinical development of a lentiviral vector for gene therapy of X-linked severe combined immunodeficiency V Poletti, S Charrier, G Corre, B Gjata, A Vignaud, F Zhang, M Rothe, ... Molecular Therapy-Methods & Clinical Development 9, 257-269, 2018 | 49 | 2018 |
| Gene-based approaches to inherited neurometabolic diseases V Poletti, A Biffi Human Gene Therapy 30 (10), 1222-1235, 2019 | 36 | 2019 |
| Gene Therapy for Sickle Cell Disease: A Lentiviral Vector Comparison Study F Urbinati, B Campo Fernandez, KE Masiuk, V Poletti, RP Hollis, C Koziol, ... Human gene therapy 29 (10), 1153-1166, 2018 | 36 | 2018 |
| The GATA1-HS2 enhancer allows persistent and position-independent expression of a β-globin transgene A Miccio, V Poletti, F Tiboni, C Rossi, A Antonelli, F Mavilio, G Ferrari PloS one 6 (12), e27955, 2011 | 32 | 2011 |
| Categorical versus dimensional thinking: improving anti-stigma campaigns by matching health message frames and implicit worldviews JH Meyer, K De Ruyter, D Grewal, K Cleeren, DI Keeling, S Motyka Journal of the academy of marketing science 48, 222-245, 2020 | 30 | 2020 |
| An optimized lentiviral vector efficiently corrects the human sickle cell disease phenotype L Weber, V Poletti, E Magrin, C Antoniani, S Martin, C Bayard, H Sadek, ... Molecular therapy Methods & clinical development 10, 268-280, 2018 | 28 | 2018 |
| Multiple integrated non-clinical studies predict the safety of lentivirus-mediated gene therapy for β-thalassemia MR Lidonnici, Y Paleari, F Tiboni, G Mandelli, C Rossi, M Vezzoli, A Aprile, ... Molecular Therapy Methods & Clinical Development 11, 9-28, 2018 | 25 | 2018 |
| Pre-clinical development of a lentiviral vector expressing the anti-sickling βAS3 globin for gene therapy for sickle cell disease V Poletti, F Urbinati, S Charrier, G Corre, RP Hollis, BC Fernandez, ... Molecular Therapy-Methods & Clinical Development 11, 167-179, 2018 | 24 | 2018 |
| Transcriptional, epigenetic and retroviral signatures identify regulatory regions involved in hematopoietic lineage commitment O Romano, C Peano, GM Tagliazucchi, L Petiti, V Poletti, F Cocchiarella, ... Scientific Reports 6 (1), 24724, 2016 | 24 | 2016 |
| Biosafety studies of a clinically applicable lentiviral vector for the gene therapy of artemis-SCID S Charrier, C Lagresle-Peyrou, V Poletti, M Rothe, G Cédrone, B Gjata, ... Molecular Therapy-Methods & Clinical Development 15, 232-245, 2019 | 19 | 2019 |
| The role of Depression on Treatment Adherence in patients with Heart Failure–a systematic review of the literature V Poletti, F Pagnini, P Banfi, E Volpato Current Cardiology Reports 24 (12), 1995-2008, 2022 | 11 | 2022 |
| Novel lentiviral vectors for gene therapy of sickle cell disease combining gene addition and gene silencing strategies M Brusson, A Chalumeau, P Martinucci, O Romano, T Felix, V Poletti, ... Molecular Therapy-Nucleic Acids 32, 229-246, 2023 | 9 | 2023 |
| Constraints on human CD34+ cell fate due to lentiviral vectors can be relieved by valproic acid A Moussy, N Papili Gao, G Corre, V Poletti, S Majdoul, D Fenard, ... Human gene therapy 30 (8), 1023-1034, 2019 | 8 | 2019 |
| Illness perceptions, cognitions, and beliefs on COPD patients’ adherence to treatment–a systematic review V Poletti, F Pagnini, P Banfi, E Volpato Patient preference and adherence, 1845-1866, 2023 | 5 | 2023 |
| Genome-wide definition of promoter and enhancer usage during neural induction of human embryonic stem cells V Poletti, A Delli Carri, G Malagoli Tagliazucchi, A Faedo, L Petiti, ... Plos one 10 (5), e0126590, 2015 | 5 | 2015 |
| An innovative hematopoietic stem cell gene therapy approach benefits CLN1 disease in the mouse model M Peviani, S Das, J Patel, O Jno‐Charles, R Kumar, A Zguro, TD Mathews, ... EMBO Molecular Medicine 15 (4), e15968, 2023 | 4 | 2023 |
